SecBot SecBot
DEFA14A ·Filed Nov 9, 2026

CRMD

CorMedix Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed7d 18h ago SEC0001213900-26-117216
Proxy solicitation materials
Actionable Insight • Neutral

Monitor Heron stockholder vote and regulatory clearances for the asset purchase. The combined entity will have four additional commercial products, significantly expanding CorMedix's revenue base. Watch for the Tranche B closing and any other acquisition funded by that facility.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

CRMD drug pipeline →

APONVIE

● Neutral Named in this DEFA14A
Impact
Phase
Approved
Time to market
Already approved and commercially available since March 2023.
Next catalyst
None dated

What to watchAPONVIE is now part of the CorMedix asset acquisition announced November 9, 2026. The deal is expected to close in Q1 2027. For Heron shareholders, the stock's value will increasingly reflect the CRMD shares and NOLs Heron retains post-close rather than APONVIE's standalone commercial trajectory. For CorMedix, APONVIE adds a growing hospital antiemetic to its institutional portfolio.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$5.47
T+0 close · Nov 9, 2026 · via day close
Latest settled
−11.88%
T+5 · $4.82
Vs SPY
−10.19%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $5.47entry
  2. T+1 · 7d ago −1.83%α −1.46% · $5.37
  3. T+5 · 20h ago −11.88%α −10.19% · $4.82
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix entered into a loan agreement with BioPharma Credit for up to $50M in Tranche B term loans, and simultaneously signed an asset purchase agreement with Heron Therapeutics to acquire multiple commercial-stage products (Cinvanti, Zynrelef, Aponvie, Sustol) for $145M in cash plus 14,583,333 shares of CorMedix common stock. The loan proceeds are designated to fund the Heron acquisition and potential other acquisitions.

Key Financial Metrics

Vote
merger approval

Key Facts

  • CorMedix entered a loan agreement with BioPharma Credit for up to $50M in Tranche B term loans dated November 8, 2026.
  • CorMedix signed an asset purchase agreement with Heron Therapeutics to acquire Cinvanti, Zynrelef, Aponvie, and Sustol.
  • Total cash consideration for the Heron acquisition is $145M plus 14,583,333 shares of CorMedix common stock.
  • The loan proceeds are to fund the Heron Acquisition Transaction and potential other acquisitions.
  • The Heron acquisition is subject to Heron stockholder approval and other closing conditions.
  • CorMedix market cap is $407M; the $145M cash consideration represents ~36% of market cap.
  • The loan agreement includes Tranche A and Tranche B facilities with makewhole and prepayment premium provisions.
  • The acquisition includes royalty and earn-out payments to Heron based on future net sales of the acquired products.

Financial Impact

CorMedix to pay $145M cash and issue 14,583,333 shares (worth ~$59M at $4.07/share based on $407M market cap and ~100M shares) for Heron's commercial products, financed partly by a $50M loan from BioPharma Credit.

revenuedilutiondebt

Risk Factors

  • Heron stockholder approval is required and may not be obtained.
  • The $145M cash consideration plus assumed liabilities represents substantial cash outlay for a $407M market cap company.
  • Issuance of 14.6M shares will dilute existing CorMedix shareholders by approximately 15%.
  • The loan carries prepayment penalties and makewhole amounts if repaid early.
  • Integration of four new commercial products carries operational and commercial risks.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-117216
Document: ea031142301ex2-1.htm0001213900-26-117216

Track record

21 reports on CRMD

Performance horizon

9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
  2. Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  3. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  4. Nov 9, 20267d ago DEFA14A Neutral 6/10 Viewing Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  5. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  6. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  7. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
  9. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
  10. Aug 13, 202613w ago 8-K Neutral 5/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026